about
Is an automatic pump suspension feature safe for children with type 1 diabetes? An exploratory analysis with a closed-loop systemEarly pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes.Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D Exchange clinic registryA tale of two compartments: interstitial versus blood glucose monitoringA contrast between children and adolescents with excellent and poor control: the T1D Exchange clinic registry experience.New-generation diabetes management: glucose sensor-augmented insulin pump therapy.Putting brakes on insulin pump infusion to prevent hypoglycemia.The alteration of aspart insulin pharmacodynamics when mixed with detemir insulin.Accuracy and precision of the Axis-Shield Afinion hemoglobin A1c measurement deviceTesting for rewards: a pilot study to improve type 1 diabetes management in adolescentsUndeniable need for ultrafast-acting insulin: the pediatric perspectiveEffect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetesEffect of insulin feedback on closed-loop glucose control: a crossover study.Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device.Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and LiraglutideAnalysis of a remote system to closely monitor glycemia and insulin pump delivery--is this the beginning of a wireless transformation in diabetes management?Reduced hypoglycemia and increased time in target using closed-loop insulin delivery during nights with or without antecedent afternoon exercise in type 1 diabetesPediatric diabetes consortium T1D New Onset (NeOn) study: clinical outcomes during the first year following diagnosis.Faster in and faster out: accelerating insulin absorption and action by insulin infusion site warming.From pumps to prevention: recent advances in the treatment of type 1 diabetes.Safety of nighttime 2-hour suspension of Basal insulin in pump-treated type 1 diabetes even in the absence of low glucose.Moving toward the ideal insulin for insulin pumps.Evaluation of Pump Discontinuation and Associated Factors in the T1D Exchange Clinic Registry.Substance Use Disorders among Patients with Type 2 Diabetes: a Dangerous but Understudied Combination.Mitigating Reductions in Glucose During Exercise on Closed-Loop Insulin Delivery: The Ex-Snacks Study.Clinical outcomes in youth beyond the first year of type 1 diabetes: Results of the Pediatric Diabetes Consortium (PDC) type 1 diabetes new onset (NeOn) study.A bridge to insulin pump therapy: twice-daily regimen with NPH and detemir insulins during initial treatment of youth with type 1 diabetes mellitus.Vitamin D status in youth with type 1 and type 2 diabetes enrolled in the Pediatric Diabetes Consortium (PDC) is not worse than in youth without diabetes.Presentation of youth with type 2 diabetes in the Pediatric Diabetes Consortium.C-peptide levels in pediatric type 2 diabetes in the Pediatric Diabetes Consortium T2D Clinic Registry.Body mass index changes in youth in the first year after type 1 diabetes diagnosis.Depressive Symptoms in Youth With Type 1 or Type 2 Diabetes: Results of the Pediatric Diabetes Consortium Screening Assessment of Depression in Diabetes Study.Diabetic ketoacidosis at diabetes onset: still an all too common threat in youth.Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study.Clinical equipoise: an argument for expedited approval of the first small step toward an autonomous artificial pancreas.Keeping Up with the Diabetes Technology: 2016 Endocrine Society Guidelines of Insulin Pump Therapy and Continuous Glucose Monitor Management of Diabetes.The need for research addressing alcohol use disorder and diabetes.Adaptive and Personalized Plasma Insulin Concentration Estimation for Artificial Pancreas Systems.The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.Plasma Insulin Estimation in People with Type 1 Diabetes Mellitus
P50
Q33740862-E384F416-D4C4-4CF4-AF05-411502B9A931Q33804562-3BB985E2-ABDD-4D4C-8A2F-608E67FF8EF1Q33908158-74FB2BC0-1ECA-43F4-AA8C-45C4694244B9Q33994026-E7412B4F-9ACF-417F-81E4-A221CDB25CC7Q34185883-1F59BC27-ABC9-4593-8DC3-1E7BB3772FCCQ35224968-7B518990-28CE-4A41-A537-692384F965BFQ35529626-EF247FF7-80EB-4E06-ADA6-ADF5B51B9D4FQ35841209-B3209A0D-3888-4D57-9726-1A9AAD72D9F5Q36051289-C0BB5BED-4CBA-4110-955B-C1BF39B7077AQ36087280-106FB7A1-0C85-44FA-AF78-3EF6F01F47C6Q36229282-22706050-8D0E-4980-9782-B1F2A2BE9505Q36249631-342141A9-7E6B-4F77-83B5-07E2B2DF7766Q36605722-573183B7-FDF8-4924-9581-ED201F4B417EQ36609298-EADE1F48-8344-4595-A3BB-48A11504B359Q37025563-82344913-8CD3-480D-AAAC-FA2BC5B769E5Q37080633-8AE35F07-F0B9-4A11-A88B-96AA67D3917DQ37193478-DF1D0444-F3F8-43A6-A24E-B9BC2A79391BQ37351231-7CEC150B-0162-4F97-8571-2F909C69B97CQ37460129-A809CE07-2E6B-4A76-BA9D-BCAB5F5DEE2CQ37542421-ECFC9CFB-2F01-4B2D-8A73-971C91CB147EQ37597019-4BDAF02A-9983-46D2-8FD9-CAE3CC832975Q38631154-0C996617-9F91-4EBF-88AD-B58CBA9D72B5Q38824221-4C50B9AB-EB0E-4BBE-B6D0-DF4D62C12791Q39013270-D931EE65-A52D-47E2-A13F-43471339C11EQ39084309-160CB37E-4545-457D-AD0B-C424F5E1C764Q39272871-2975E19D-E1E7-4FA1-8159-499397E0CF6DQ39982190-B7844CB7-67E9-4C69-8119-499C5AE5ED1CQ40269678-666F0310-5C7F-4363-B789-035E22AA630DQ40964404-6EEC1FB1-EF31-4CD1-8879-3728E6F356B1Q40976863-E6F1A797-7DF3-4EF7-8475-E7CFCEC6B5E9Q41004916-8BD9E66E-1C7E-4446-8D01-D9B2F9830B8DQ41231532-0647AB27-9DF8-4C8E-BFFA-BEA265B93CD3Q44667056-8D5BEF99-E366-421E-9973-E121FE6DC72DQ47722005-59A07947-9523-4C77-9C3A-0A9E09AC9187Q48399179-9BEBC5EC-EAFF-4AB6-B593-A67B174EE365Q49887494-D95B1C25-854C-4956-B5A3-65A2859F2AEEQ52308148-ADEDE513-73FB-41A9-9C76-ADE8C69ACD36Q52642465-0C610BD4-6FEB-4DBF-82BF-677D1F0CA265Q53449720-327B66D8-344F-425C-AC80-4E281AC81009Q62636678-44654F8E-8C1C-4326-843E-50ACEDF0DCA8
P50
name
Eda Cengiz
@ast
Eda Cengiz
@en
Eda Cengiz
@nl
type
label
Eda Cengiz
@ast
Eda Cengiz
@en
Eda Cengiz
@nl
prefLabel
Eda Cengiz
@ast
Eda Cengiz
@en
Eda Cengiz
@nl